Monday, January 17, 2022

Tag: AST-OPC1

A Year Ago He Was Paralyzed From the Neck Down — Then This Happened

You might feel a bit down if you watch the news. Who wouldn’t? Angry people might be grabbing headlines and making you wonder about the...

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10,...

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at...

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on...

Generating improvement in spinal cord injuries

Early clinical trial results announced offer new hope in regenerative medicine A new therapy to treat spinal cord injuries in people who have lost all...

Paralyzed Man Regains Use of Arms and Hands After Experimental Stem Cell Therapy at...

Initial Results Offer Hope for Patients to Reclaim Independence After Suffering Severe Spinal Injury LOS ANGELES, Sept. 7, 2016 /PRNewswire/ -- Keck Medical Center...

Stem Cell Agency Spinal Cord Injury Clinical Trial Passes Safety Hurdles

Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and...

Stem Cells vs. Spinal Cord Injuries

A paralyzing injury to the neck during recreational activities such as horseback riding or playing football usually has permanent, lifelong effects that change a...

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord...

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one...